Low-dose Colchicine for CABG Graft Failure Prevention

Inclusion Criteria: 1. Be male or female, aged 18 years or older; 2. Within 3 days after successful isolated coronary artery bypass grafting (CABG); 3. Sign informed consent; Exclusion Criteria: 1. Severe valvular heart disease requiring concomitant or staged valvular surgery; 2. History of non-skin cancer in the past 3 years; 3. Inflammatory bowel disease or chronic diarrhea; 4. Neuromuscular diseases or non-transient creatine kinase levels greater than 3 times the upper limit of the normal range (except those associated with myocardial infarction); 5. Clinically significant non-transient (At least 2 laboratory tests) blood abnormalities (Hemoglobin \<100g/L or hematocrit \< 30% or \> 52% or white blood cell count \< 3×109/L or platelet count \< 100×109/L); 6. Estimated glomerular filtration rate (eGFR) \< 30 mL/min/1.73 m² (based on the CKDEPI formula); 7. Serum alanine aminotransferase and/or aspartate aminotransferase levels greater than 2 times the upper limit of the normal range, accompanied by serum total bilirubin levels greater than 2 times the upper limit of the normal range or severe liver disease with coagulation disorders (INR\>1.5) (except for elevated glutamic oxalacetic transaminase associated with myocardial infarction); 8. Decline in cognitive function due to inability to perform basic activities of daily living independently; 9. Drug or alcohol abuse; 10. Other immunosuppressive therapies already in existence or planned; 11. Other causes require long-term colchicine treatment; 12. History of clear or suspected colchicine allergy; 13. Strong CYP3A4 or P-glycoprotein inhibitors (such as cyclosporine, antiretrovirals, antifungals, erythromycin and clarithromycin) have been used and no other alternative drugs can be used.